HSE pays 47% more for 'brand name' drugs

A new survey has found that Ireland's Health Service is paying one-and-a-half times more than Britain for brand name medicines.

The study carried out for the Swedish pharmaceutical sector shows that Ireland pays more than any other Northern European country for drugs that are still under patent.

The survey found that the HSE pays 47% more than Britain's NHS for such "brand name" drugs.